Alemtuzumab
Most Relevant Related Tags
- bevacizumab [6%]
- multiple sclerosis [4%]
- clinical trial [4%]
- monoclonal antibodies [4%]
- trastuzumab [4%]
- gemtuzumab ozogamicin [4%]
- panitumumab [2%]
- palivizumab [2%]
- ocrelizumab [2%]
- omalizumab [2%]
- opportunistic infection [2%]
- pascolizumab [2%]
- ranibizumab [2%]
- receptor tyrosine kinase [2%]
- pubchem [2%]
- protein kinase inhibitor [2%]
- pertuzumab [2%]
- pexelizumab [2%]
- non-hodgkin lymphoma [2%]
- nervous system [2%]
This is the cloud of related tags for the Alemtuzumab concept
aflibercept afutuzumab alacizumab pegol alkylating antineoplastic agent anatomical therapeutic chemical classification system antigen antineoplastic apolizumab aselizumab atlizumab australia autoimmune disease axitinib bapineuzumab bevacizumab bioavailability biological half-life bivatuzumab mertansine bosutinib cas registry number cancer immunotherapy cantuzumab mertansine cedelizumab cediranib certolizumab pegol cetuximab chemical formula chemotherapy chronic lymphocytic leukemia citatuzumab bogatox clinical trial cytomegalovirus dacetuzumab daclizumab dasatinib denileukin diftitox drugbank drug metabolism eculizumab edrecolomab efalizumab elotuzumab epcam epidermal growth factor receptor epratuzumab erlizumab erlotinib etaracizumab excretion farletuzumab felvizumab fludarabine fontolizumab fusion protein gefitinib gemtuzumab ozogamicin greg winter herman waldmann humanized antibody ibalizumab imatinib immune system inotuzumab ozogamicin interleukin kidney transplantation labetuzumab lapatinib lebrilizumab lestaurtinib lintuzumab lymphocyte matuzumab mepolizumab milatuzumab monoclonal antibodies motavizumab multiple sclerosis natalizumab neratinib nervous system new scientist nilotinib nimotuzumab non-hodgkin lymphoma ocrelizumab omalizumab opportunistic infection palivizumab panitumumab pascolizumab pertuzumab pexelizumab protein kinase inhibitor pubchem ranibizumab receptor tyrosine kinase regulation of therapeutic goods reslizumab rituximab route of administration rovelizumab ruplizumab semaxanib sibrotuzumab siplizumab sorafenib stem cell sunitinib tacatuzumab tetraxetan tadocizumab talizumab tanezumab tefibazumab teplizumab tigatuzumab tocilizumab toralizumab tositumomab toxin trastuzumab tucotuzumab celmoleukin tumor tyrosine kinase urtoxazumab vandetanib vascular endothelial growth factor a vedolizumab veltuzumab visilizumab